316 related articles for article (PubMed ID: 32459663)
1. COVID-19, microangiopathy, hemostatic activation, and complement.
Song WC; FitzGerald GA
J Clin Invest; 2020 Aug; 130(8):3950-3953. PubMed ID: 32459663
[No Abstract] [Full Text] [Related]
2. Complement as a target in COVID-19?
Risitano AM; Mastellos DC; Huber-Lang M; Yancopoulou D; Garlanda C; Ciceri F; Lambris JD
Nat Rev Immunol; 2020 Jun; 20(6):343-344. PubMed ID: 32327719
[TBL] [Abstract][Full Text] [Related]
3. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications.
Merrill JT; Erkan D; Winakur J; James JA
Nat Rev Rheumatol; 2020 Oct; 16(10):581-589. PubMed ID: 32733003
[TBL] [Abstract][Full Text] [Related]
4. Thrombotic microangiopathy in a patient with COVID-19.
Jhaveri KD; Meir LR; Flores Chang BS; Parikh R; Wanchoo R; Barilla-LaBarca ML; Bijol V; Hajizadeh N
Kidney Int; 2020 Aug; 98(2):509-512. PubMed ID: 32525010
[No Abstract] [Full Text] [Related]
5. Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily.
Gavriilaki E; Brodsky RA
Br J Haematol; 2020 Jun; 189(6):e227-e230. PubMed ID: 32369610
[No Abstract] [Full Text] [Related]
6. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): a new variant of thrombotic microangiopathy?
Bobrova L; Kozlovskaya N; Korotchaeva Y; Bobkova I; Kamyshova E; Moiseev S
Crit Care Resusc; 2020 Sep; 22(3):284. PubMed ID: 32900338
[No Abstract] [Full Text] [Related]
7. COVID-19: Complement, Coagulation, and Collateral Damage.
Lo MW; Kemper C; Woodruff TM
J Immunol; 2020 Sep; 205(6):1488-1495. PubMed ID: 32699160
[TBL] [Abstract][Full Text] [Related]
8. [Thrombotic microangiopathy: A renal manifestation in SARS-CoV-2 infection (COVID-19 disease)].
Marcilla Vázquez C; Vidal Company A; Navarro Felipe A; Alfaro Ponce B
An Pediatr (Engl Ed); 2020 Nov; 93(5):352-353. PubMed ID: 32943329
[No Abstract] [Full Text] [Related]
9. Diabetes and severity of COVID-19: What is the link?
Pitocco D; Viti L; Tartaglione L; Di Leo M; Rizzo GE; Manto A; Rizzi A; Caputo S; Pontecorvi A
Med Hypotheses; 2020 Oct; 143():109923. PubMed ID: 32485315
[TBL] [Abstract][Full Text] [Related]
10. Ischemic-hemorrhagic stroke in patients with Covid-19.
Azpiazu Landa N; Velasco Oficialdegui C; Intxaurraga Fernández K; Gonzalez Larrabe I; Riaño Onaindia S; Telletxea Benguria S
Rev Esp Anestesiol Reanim (Engl Ed); 2020 Nov; 67(9):516-520. PubMed ID: 33012537
[TBL] [Abstract][Full Text] [Related]
11. COVID-19: disCOVering the role of complement system.
Conigliaro P; Triggianese P; Perricone C; Chimenti MS; Perricone R
Clin Exp Rheumatol; 2020; 38(4):587-591. PubMed ID: 32723436
[No Abstract] [Full Text] [Related]
12. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome.
Quartuccio L; Semerano L; Benucci M; Boissier MC; De Vita S
Joint Bone Spine; 2020 May; 87(3):191-193. PubMed ID: 32321634
[No Abstract] [Full Text] [Related]
13. Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders.
Araten DJ; Belmont HM; Schaefer-Cutillo J; Iyengar A; Mattoo A; Reddy R
Am J Case Rep; 2020 Sep; 21():e927418. PubMed ID: 32917848
[TBL] [Abstract][Full Text] [Related]
14. Immune-Mediated Coagulopathy in COVID-19 Infection.
Vadasz Z; Brenner B; Toubi E
Semin Thromb Hemost; 2020 Oct; 46(7):838-840. PubMed ID: 32877959
[No Abstract] [Full Text] [Related]
15. Pulmonary Embolism, Pulmonary Microvascular Thrombosis, or Both in COVID-19?
Páramo JA
Clin Appl Thromb Hemost; 2020; 26():1076029620933953. PubMed ID: 32697603
[No Abstract] [Full Text] [Related]
16. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Mastellos DC; Pires da Silva BGP; Fonseca BAL; Fonseca NP; Auxiliadora-Martins M; Mastaglio S; Ruggeri A; Sironi M; Radermacher P; Chrysanthopoulou A; Skendros P; Ritis K; Manfra I; Iacobelli S; Huber-Lang M; Nilsson B; Yancopoulou D; Connolly ES; Garlanda C; Ciceri F; Risitano AM; Calado RT; Lambris JD
Clin Immunol; 2020 Nov; 220():108598. PubMed ID: 32961333
[TBL] [Abstract][Full Text] [Related]
17. A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19.
Martinelli N; Montagnana M; Pizzolo F; Friso S; Salvagno GL; Forni GL; Gianesin B; Morandi M; Lunardi C; Lippi G; Polati E; Olivieri O; De Franceschi L
Thromb Res; 2020 Sep; 193():170-172. PubMed ID: 32707276
[No Abstract] [Full Text] [Related]
18. Hemostasis profile in COVID-19 infection.
Duarte FB; Machado RPG; Lemes RPG; Duarte IA; Duarte BA; Machado CMG; Duarte JVA; Rocha SGMD; Moura ATG; Holanda RARR
Rev Assoc Med Bras (1992); 2020 May; 66(5):571-572. PubMed ID: 32638971
[No Abstract] [Full Text] [Related]
19. Terminal complement inhibition dampens the inflammation during COVID-19.
Kulasekararaj AG; Lazana I; Large J; Posadas K; Eagleton H; Lord Villajin J; Zuckerman M; Gandhi S; Marsh JCW
Br J Haematol; 2020 Aug; 190(3):e141-e143. PubMed ID: 32495372
[No Abstract] [Full Text] [Related]
20. COVID-19 coagulopathy vs disseminated intravascular coagulation.
Levi M
Blood Adv; 2020 Jun; 4(12):2850. PubMed ID: 32574369
[No Abstract] [Full Text] [Related]
[Next] [New Search]
